{"title":"摘要:确定墨西哥奇瓦瓦州人群中砷相关膀胱癌的表观遗传基础","authors":"R. Fry","doi":"10.1158/1538-7755.DISP17-IA16","DOIUrl":null,"url":null,"abstract":"Epidemiologic evidence links chronic exposure to inorganic arsenic (iAs) to a host of adverse health effects, including cancer of the bladder. This study aimed to identify DNA methylation patterns associated with arsenic and its metabolites in exfoliated urothelial cells (EUCs) that originate primarily from the urinary bladder, one of the targets of arsenic-induced carcinogenesis. EUCs from 46 residents of Chihuahua, Mexico were analyzed for genome-wide, gene-specific promoter DNA methylation levels. These were analyzed in relation to intracellular concentrations of total arsenic and arsenic species. A set of 49 differentially methylated genes was identified with increased promoter methylation associated with EUC tAs, iAs, and/or monomethylated As (MMAs) enriched for their roles in metabolic disease and cancer. Notably, no genes had differential methylation associated with EUC dimethylated As (DMAs), suggesting that DMAs may influence DNA methylation-mediated urothelial cell responses to a lesser extent than iAs or MMAs. Further analysis showed that 22 of the 49 arsenic-associated genes (45%) are also differentially methylated in bladder cancer tissue identified using The Cancer Genome Atlas (TCGA) repository. Both the arsenic- and cancer-associated genes were enriched for the binding sites of common transcription factors known to play roles in carcinogenesis, demonstrating a novel potential mechanistic link between iAs exposure and bladder cancer. Citation Format: Rebecca C. Fry, Rebecca C. Fry. Identifying an epigenetic basis for arsenic-associated bladder cancer in a population in Chihuahua Mexico [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr IA16.","PeriodicalId":287118,"journal":{"name":"Global Health and Environmental Exposures","volume":"1 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2018-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":"{\"title\":\"Abstract IA16: Identifying an epigenetic basis for arsenic-associated bladder cancer in a population in Chihuahua Mexico\",\"authors\":\"R. Fry\",\"doi\":\"10.1158/1538-7755.DISP17-IA16\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Epidemiologic evidence links chronic exposure to inorganic arsenic (iAs) to a host of adverse health effects, including cancer of the bladder. This study aimed to identify DNA methylation patterns associated with arsenic and its metabolites in exfoliated urothelial cells (EUCs) that originate primarily from the urinary bladder, one of the targets of arsenic-induced carcinogenesis. EUCs from 46 residents of Chihuahua, Mexico were analyzed for genome-wide, gene-specific promoter DNA methylation levels. These were analyzed in relation to intracellular concentrations of total arsenic and arsenic species. A set of 49 differentially methylated genes was identified with increased promoter methylation associated with EUC tAs, iAs, and/or monomethylated As (MMAs) enriched for their roles in metabolic disease and cancer. Notably, no genes had differential methylation associated with EUC dimethylated As (DMAs), suggesting that DMAs may influence DNA methylation-mediated urothelial cell responses to a lesser extent than iAs or MMAs. Further analysis showed that 22 of the 49 arsenic-associated genes (45%) are also differentially methylated in bladder cancer tissue identified using The Cancer Genome Atlas (TCGA) repository. Both the arsenic- and cancer-associated genes were enriched for the binding sites of common transcription factors known to play roles in carcinogenesis, demonstrating a novel potential mechanistic link between iAs exposure and bladder cancer. Citation Format: Rebecca C. Fry, Rebecca C. Fry. Identifying an epigenetic basis for arsenic-associated bladder cancer in a population in Chihuahua Mexico [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr IA16.\",\"PeriodicalId\":287118,\"journal\":{\"name\":\"Global Health and Environmental Exposures\",\"volume\":\"1 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2018-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"1\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Global Health and Environmental Exposures\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1158/1538-7755.DISP17-IA16\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Global Health and Environmental Exposures","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1158/1538-7755.DISP17-IA16","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
摘要
流行病学证据表明,长期接触无机砷与包括膀胱癌在内的一系列不利健康影响有关。本研究旨在鉴定主要源自膀胱的脱落尿路上皮细胞(EUCs)中与砷及其代谢物相关的DNA甲基化模式,膀胱是砷诱导癌变的靶点之一。对来自墨西哥奇瓦瓦州46名居民的EUCs进行了全基因组、基因特异性启动子DNA甲基化水平的分析。分析了这些与细胞内总砷浓度和砷种类的关系。一组49个差异甲基化基因被鉴定出与EUC tAs、iAs和/或单甲基化As (MMAs)相关的启动子甲基化增加,这些基因在代谢性疾病和癌症中发挥着丰富的作用。值得注意的是,没有基因存在与EUC二甲基化As (DMAs)相关的差异甲基化,这表明DMAs对DNA甲基化介导的尿路上皮细胞反应的影响程度可能低于iAs或MMAs。进一步的分析表明,49个砷相关基因中有22个(45%)在膀胱癌组织中也存在差异甲基化,这些基因是通过癌症基因组图谱(TCGA)库确定的。砷和癌症相关基因都富集了已知在致癌过程中起作用的常见转录因子的结合位点,这表明砷暴露与膀胱癌之间存在一种新的潜在机制联系。引文格式:Rebecca C. Fry, Rebecca C. Fry。确定墨西哥奇瓦瓦州人群中砷相关膀胱癌的表观遗传基础[摘要]。见:第十届AACR会议论文集:种族/少数民族和医疗服务不足人群的癌症健康差异科学;2017年9月25-28日;亚特兰大,乔治亚州。费城(PA): AACR;癌症流行病学杂志,2018;27(7增刊):摘要11 - 16。
Abstract IA16: Identifying an epigenetic basis for arsenic-associated bladder cancer in a population in Chihuahua Mexico
Epidemiologic evidence links chronic exposure to inorganic arsenic (iAs) to a host of adverse health effects, including cancer of the bladder. This study aimed to identify DNA methylation patterns associated with arsenic and its metabolites in exfoliated urothelial cells (EUCs) that originate primarily from the urinary bladder, one of the targets of arsenic-induced carcinogenesis. EUCs from 46 residents of Chihuahua, Mexico were analyzed for genome-wide, gene-specific promoter DNA methylation levels. These were analyzed in relation to intracellular concentrations of total arsenic and arsenic species. A set of 49 differentially methylated genes was identified with increased promoter methylation associated with EUC tAs, iAs, and/or monomethylated As (MMAs) enriched for their roles in metabolic disease and cancer. Notably, no genes had differential methylation associated with EUC dimethylated As (DMAs), suggesting that DMAs may influence DNA methylation-mediated urothelial cell responses to a lesser extent than iAs or MMAs. Further analysis showed that 22 of the 49 arsenic-associated genes (45%) are also differentially methylated in bladder cancer tissue identified using The Cancer Genome Atlas (TCGA) repository. Both the arsenic- and cancer-associated genes were enriched for the binding sites of common transcription factors known to play roles in carcinogenesis, demonstrating a novel potential mechanistic link between iAs exposure and bladder cancer. Citation Format: Rebecca C. Fry, Rebecca C. Fry. Identifying an epigenetic basis for arsenic-associated bladder cancer in a population in Chihuahua Mexico [abstract]. In: Proceedings of the Tenth AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2017 Sep 25-28; Atlanta, GA. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2018;27(7 Suppl):Abstract nr IA16.